~|elegant-themes~|elegant-themes-icon~|~

This report is for Members only | Already a Member? Sign in

To continue reading, choose your Membership package from the options below

ANNUAL MEMBERSHIP

USD 49/year
Unlimited access to my very best investment ideas:
~|elegant-themes~|elegant-themes-icon~|Z

10 extensive research reports per year

~|elegant-themes~|elegant-themes-icon~|Z

Updates on previous research reports

~|elegant-themes~|elegant-themes-icon~|Z

Email alerts for reports and updates

~|elegant-themes~|elegant-themes-icon~|Z

Archive with all past research reports

LIFETIME MEMBERSHIP

USD 999/one-off

All the benefits of the Annual Membership package, plus:

~|elegant-themes~|elegant-themes-icon~|Z

4 additional investment opportunities each year, sourced from small- and mid-caps (i.e., less liquid markets)

~|elegant-themes~|elegant-themes-icon~|Z

Priority booking of reader events and trips

Most recent

The Economist: a good investment?

The Economist: a good investment?

It’s little-known, but The Economist has over 1,000 shareholders. It’s akin to an exclusive club, which rather wants to keep you out. Will you be able to buy stock regardless – and could a proper IPO beckon?

read more

Latest reports (for Members only)

Bayer AG: similar to buying Volkswagen two years ago?

Bayer AG: similar to buying Volkswagen three years ago?

German blue chip Bayer is currently down and out. 2022 should bring a turnaround, though, similar to the one seen at Volkswagen.

A groundfloor opportunity in gaming and esports

A groundfloor opportunity in gaming and esports

This European entertainment champion is looking to turn itself into a global giant - and could gain 125% by mid-2022.

Novavax: The "best" coronavirus vaccine and an undervalued stock?

Novavax: The "best" coronavirus vaccine and an undervalued stock?

Can coronavirus vaccine maker Novavax profit from the vast majority of unvaccinated people, and make vaccine sceptics fall in love with it?